前列腺MRI深度学习分类显著癌的系统综述与Meta分析
本系统综述与Meta分析检索PubMed、Embase和ClinicalTrials.gov,纳入7项研究,评估深度学习模型对MRI上临床显著前列腺癌(Gleason分级组≥2)的分类性能。汇总的患者水平AUC为0.83 [0.80, 0.86]。未来研究应优先开展前瞻性临床试验并标准化报告指标。
要点
- 深度学习对MRI上临床显著前列腺癌的汇总患者水平AUC为0.83 [0.80, 0.86]。
- 多数研究为回顾性设计,使用不同机构数据进行外部验证。
- 未来需前瞻性试验、标准化报告及与资深放射科医生的直接比较。
核心结论
- 深度学习对MRI上临床显著前列腺癌的分类性能具有前景,汇总患者水平AUC为0.83 [0.80, 0.86]。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和ClinicalTrials.gov。
- 共387项潜在相关研究,最终7项纳入Meta分析。
- 6项研究为回顾性设计,使用不同机构数据进行外部验证。
- 1项研究同时采用回顾性与前瞻性设计,在前瞻性数据集上验证模型。
诊断标准与关键数值
- 临床显著前列腺癌定义为Gleason分级组≥2。
- 在双参数或多参数MRI上评估端到端深度学习分类模型。
- 汇总的患者水平AUC为0.83 [0.80, 0.86]。
临床应用与阅片要点
- 深度学习图像分析可整合入前列腺癌诊断路径以改善活检决策。
- 深度学习可减少放射科医生阅片时间并降低阅片者间差异。
局限性
- 多数纳入研究为回顾性设计,缺乏前瞻性验证。
- 研究间报告指标不统一,缺乏与资深放射科医生的直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Deep learning (DL) image analysis of prostate MRI can be integrated into the prostate cancer diagnostic pathway to improve biopsy decision making, reduce radiologist interpretation time, and decrease inter-reader variability. In this paper, we systematically review the current literature on DL classification of clinically significant prostate cancer detected on magnetic resonance imaging and perform a meta-analysis of reported external validation performance metrics. A literature search was performed on PubMed, Embase, and ClinicalTrials.gov to identify studies describing end-to-end DL classification models that distinguish clinically significant prostate cancer (defined as Gleason Grade Group ≥ 2) on biparametric or multiparametric MRI. Information on the data sources used for model training and external validation, reference standards, imaging sequences, DL architectures, model inputs, the use of gradient-weighted class activation mapping (GRAD-CAM) or saliency maps, and the area under the receiver operating characteristic curve (AUC) was extracted. Out of 387 potentially relevant studies, 7 were included in the final meta-analysis. 6 studies were retrospective in design and performed external validation using data from different institutions. One study employed both retrospective and prospective designs, validating the model on the prospective dataset. The pooled patient-level AUC was 0.83 [0.80, 0.86]. While current performance is promising, future research should prioritize prospective clinical trials, standardize reporting measures, and include direct comparisons to experienced radiologists. To ensure the development of widely generalizable models, future studies should evaluate performance on shared, large, and diverse datasets, enabling meaningful cross-study comparisons.
引用
- Chung, Michalak, Rubinov, et al. Deep learning classification of significant prostate cancer on MRI: a systematic review and meta-analysis. Abdom Radiol (NY). 2026. PMID: 42364040. doi:10.1007/s00261-026-05639-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。